According to a recent LinkedIn post from C Ray Therapeutics, the China-based radiopharmaceutical CRDMO plans to participate in ANZSNM2026 in Canberra from May 15–17, where it will be present at Booth 48. The post highlights the company’s interest in engaging with potential partners across development collaborations, isotope pilot projects, and clinical research alliances.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post describes C Ray Therapeutics’ service scope as spanning PCC selection, pre-clinical evaluation, CMC development, IND filing, clinical supply, and commercial cGMP manufacturing. It also notes that the company has completed more than 100 CRDMO projects, including two programs reported to be in Phase III and 23 projects labeled with Ac‑225.
For investors, the post suggests that C Ray Therapeutics is positioning itself as an integrated partner in the radiopharmaceutical value chain, with capabilities that extend from early research through late-stage clinical development and manufacturing. This breadth may enhance its appeal to global biopharma clients seeking outsourced development and manufacturing support in targeted radiotherapies.
The emphasis on Ac‑225 and Lu‑177 work, together with participation in a regional nuclear medicine meeting, indicates a focus on high-value radioligand therapies, an area of growing strategic interest among oncology and radiopharma developers. If the company can leverage conference visibility into new partnerships and long-term supply agreements, it could strengthen revenue visibility and reinforce its competitive position in the radiopharmaceutical CDMO/CRDMO segment.